Abstract: The present invention relates to compounds of formula (Ib), wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.

Abstract: A shift register, a driving circuit, a driving method and a display device are provided. The shift register includes: an input circuit configured to provide a first voltage or a second voltage to a first node and a light-emitting control signal terminal under a control of a first input signal and a second input signal; a processing circuit configured to provide the first voltage or the second voltage to a second node under a control of the first input signal and a potential of the first node; and an output circuit configured to provide the first voltage or the second voltage to a first output scanning signal terminal under control of a first clock signal and the potential of the first node, and provide the first voltage or the second voltage to a second output scanning signal terminal under a control of a potential of the first output scanning signal terminal.

Abstract: The present disclosure provides a gate driving circuit, a method of driving a gate driving circuit, and a display panel. The gate driving circuit includes a plurality of driving units connected in cascade. Each driving unit includes: N shift register units; and a mode control circuit connected to the N shift register units, wherein the mode control circuit is configured to receive a control signal for the driving unit, and connect the N shift register units in one of a plurality of resolution modes under the control of the control signal.

Abstract: A display method is provided. The display method includes providing a display panel having a plurality of subpixels, a respective subpixel of the plurality of subpixels including a first area, n1 number of second areas, and n2 number of third areas, the first area being between the n1 number of second areas and the n2 number of third areas, n1?1, and n2?1; for displaying a first frame of image, controlling light emission of the respective subpixel to be limited in the first area, m1 number of the n1 number of second areas, and m2 number of the n2 number of third areas; and for displaying a second frame of image, controlling light emission of the respective subpixel to be limited in the first area, m1? number of the n1 number of second areas, and m2? number of the n2 number of third areas.

Abstract: The present disclosure provides a display substrate, a preparing method thereof, and a display device. The display substrate includes: a base substrate including a spacing region; a plurality of light-emitting device groups on the base substrate, any two adjacent light-emitting device groups of the plurality of light-emitting device groups being spaced apart from each other by the spacing region; and a light-shielding layer on the base substrate. The light-shielding layer covers the plurality of light-emitting device groups and fills the spacing region, a first portion of the light-shielding layer covering the plurality of light-emitting device groups has a first thickness, a second portion of the light-shielding layer filling the spacing region has a second thickness, the first thickness is less than the second thickness.

Abstract: The present disclosure relates to a display panel and a terminal device. The display panel includes a display region. At least a part of the display region is a transparent region. The transparent region has a plurality of pixel rows distributed along a column direction, and each of the plurality of pixel rows includes pixels and transparent portions arranged in a row direction. The pixel rows include first pixel rows and second pixel rows, transparent portions each arranged between two adjacent pixels in each of the first pixel rows are first transparent portions, and transparent portions each arranged between two adjacent pixels in each of the second pixel rows are second transparent portions. A width of each of the first transparent portions in the row direction is greater than a width of each of the second transparent portions in the row direction.

Abstract: The present invention relates to compounds of formula (Ib), wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: This application provides a data transmission apparatus and a data transmission method. The data transmission apparatus in this application includes: a first connection unit and a control unit, where the first connection unit is a connector plug or a connector socket; and the control unit is configured to: if determining that the first connection unit is in a forward insertion state, control a first data pin pair of the first connection unit to be in a first communication mode, and control a second data pin pair of the first connection unit to be in a second communication mode.

Abstract: An apparatus with a forward-reverse insertion interface and a detection method are provided, and relate to the field of communication technologies, to improve transmission efficiency of an auxiliary channel. The forward-reverse insertion interface of the apparatus includes: a first auxiliary channel (CH1), including a first switch selection circuit (SW1) coupled to a first node (A); a second auxiliary channel (CH2), including a second switch selection circuit (SW2) coupled to a second node (B), where the second switch selection circuit (SW2) and the first switch selection circuit (SW1) are structurally asymmetrical; and a control circuit (CTRL), configured to control switching of the first switch selection circuit (SW1) to change an electrical parameter of the first node (A), and control switching of the second switch selection circuit (SW2) to change an electrical parameter of the second node (B).

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention provides a knowledge graph construction method and device. The method includes: obtaining structured data, where the structured data includes a first entity name of a first entity and attribute information corresponding to the first entity name, and the attribute information includes a first attribute and a first attribute value; performing, based on measurement of a similarity between the first entity and a second entity in a knowledge graph, entity alignment processing on the first entity, where the measurement of the similarity includes at least one of the following types: measurement of a character similarity, measurement of a structure similarity of a classification tree on which an entity is located, and measurement of an attribute similarity; and importing the structured data into the knowledge graph according to an entity alignment processing result. Embodiments may ensure correctness of data in the knowledge graph.

Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds act as antagonists of the toll-like receptors TLR7, TLR8 and/or TLR9 and are thus useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R3, Y and A are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: A method and a device for controlling a remotely controlled mobile platform and a readable storage medium are provided. The method includes: displaying at least one function icon and at least one control icon, where the function icon represents a control program for implementing a preset function, and the control icon is used to control a control terminal and/or a remotely controlled mobile platform to execute the control program; generating, based on a selection operation of a user on the function icon, the control program associated with the selected function icon; and controlling, based on an operation of the user on the control icon, the control terminal and/or the remotely controlled mobile platform to execute the control program.

Abstract: The present invention relates to compounds of formula (I), wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.